Part the Cloud Translational Research supports academic investigators and small companies in testing treatments and disease-progression biomarkers to advance Alzheimer’s and related dementia research.
Full application deadlines moved from December 15, 2026 to January 5, 2027, and for ISTAART members from December 17, 2026 to January 7, 2027 (5 p.m. ET). Repurposed-drug study guidance also replaces “pre-symptomatic” with a repeated “symptomatic.”
Part the Cloud Combination Therapies Program supports researchers conducting Phase 1–3 trials of combined therapies for Alzheimer’s and related dementias to inform further treatment development.
PTC-EM-AI supports researchers advancing AI-discovered therapies for Alzheimer's and related dementias through lead optimization and IND-enabling studies to prepare candidates for clinical development.
Tau Pipeline Enabling Program V (T-PEP) supports researchers developing therapeutic candidates targeting tau or related mechanisms to advance potential disease-modifying treatments for tauopathies.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
Prevention RFP - Alzheimer's Drug Discovery Foundation supports researchers and clinicians conducting human studies of targeted interventions, combination therapies, and drug choices to reduce dementia risk.